Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Preparation method and application of live vector vaccine for expressing duck Tembusu virus (DTMUV) prm and E protein recombinant Newcastle disease virus (NDV)

A technology of duck Tembusu virus and Newcastle disease virus, which is applied in the preparation and application of live vector vaccines, can solve the problems of strong virulence and low virus titer, and achieve the effect of reducing detoxification

Active Publication Date: 2017-03-22
INST OF ANIMAL HEALTH GUANGDONG ACADEMY OF AGRI SCI +1
View PDF1 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] At present, duck Tembusu virus inactivated vaccine (HB strain) has been on the market, but research has found that the inactivated vaccine requires more than two immunizations to achieve a good immune effect, and the virus of the approved duck Tembusu virus live vaccine The potency is not high, and it has the potential of strong virulence

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Preparation method and application of live vector vaccine for expressing duck Tembusu virus (DTMUV) prm and E protein recombinant Newcastle disease virus (NDV)
  • Preparation method and application of live vector vaccine for expressing duck Tembusu virus (DTMUV) prm and E protein recombinant Newcastle disease virus (NDV)
  • Preparation method and application of live vector vaccine for expressing duck Tembusu virus (DTMUV) prm and E protein recombinant Newcastle disease virus (NDV)

Examples

Experimental program
Comparison scheme
Effect test

experiment example 1

[0032] Construction of the full-length plasmid of experimental example 1 attenuated GM strain

[0033] Newcastle disease GM strain (GenBank accession no. DQ486859) full-length cDNA cloning plasmid (TVT-GM) rescued virus is a virulent strain, which has potential biological safety hazards. In order to weaken the virus, this study designed two pairs of primers (see Table 1). After PCR amplification of the TVT-GM plasmid, two mutant fragments were obtained, and then the fragment of the mutant F protein cleavage site sequence was obtained by fusion PCR ( named Fa). After the Fa fragment and the TVT-GM plasmid were digested by Age I and Asc I respectively, the Fa fragment and the fragment of about 14 kb after digestion of the TVT-GM plasmid were recovered, and they were ligated with T4 DNA ligase. The ligation product was transformed into DH5α competent, and the plasmid was extracted by Qiagen QIAprep Spin Miniprep Kit, which was the attenuated full-length plasmid, which was confir...

experiment example 2

[0038] Experimental example 2 Construction of recombinant Newcastle disease virus plasmid expressing duck Tembusu virus prm and E protein

[0039] In order to enable the foreign gene to be successfully inserted into the Newcastle disease virus, on the basis of obtaining the attenuated full-length plasmid TVT-aGM, design the Pme-6200U and Pme-6193L primers (Table 2), and use the upstream primer F1- Mut-U and Pme-6193L primers amplified a 290bp fragment, while Pme-6200U and downstream primer F2-Mut-L were used to amplify a 3629bp fragment. Subsequently, using the recovered product as a template, PCR amplification was performed using F1-Mut-U and F2-Mut-L primers, and the obtained fragment was ligated with the pMD18T vector and named as Fa-Pme. Subsequently, use JM-prm / E-U and JM-prm / E-L primers to amplify duck Tembusu virus JM strain (preservation number is CCTCC NO: V201131) nucleic acid, obtain prm and E gene fragments (GenBankaccession number: JN811559), length It is 2080bp....

experiment example 3

[0043] Identification of Experimental Example 3 Recombinant Virus aGM-prm / E

[0044] The eukaryotic expression plasmids pCI-NP, pCI-P and pCI-L expressing the Newcastle disease virus NP, P and L genes constructed by the pCI-neo plasmid of Promega Company respectively, according to the method of Lipofectamine LTX instructions, the full-length plasmid TVT- aGM and helper plasmids pCI-NP, pCI-P and pCI-L were co-transfected into BSR-T7 / 5 cells converging 90% of the cell plate at a ratio of 2:2:1:1. 24 hours after transfection, TPCK trypsin or 10% SPF chick embryo allantoic fluid was added at a final concentration of 1 μg / μL. After 72 hours of transfection, the cells were repeatedly frozen and thawed three times, and the mixture was inoculated into 9-day-old SPF chicken embryos, 0.5 mL / embryo. The dead embryos within 24 hours were discarded, the allantoic fluid of all dead and surviving chicken embryos were harvested within 24-120 hours, and the HA titers were determined respecti...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a preparation method for expressing the duck Tembusu virus (DTMUV) prm and the E protein recombinant Newcastle disease virus (NDV). The preparation method comprises the following steps: 1) constructing full-length plasmids of an attenuated ND GM strain; 2) constructing plasmids for expressing the DTMUV prm and the E protein recombinant NDV; 3) rescuing and identifying the recombinant virus aGM-prm / E. The invention also discloses the virus aGM-prm / E prepared by the method. The virus aGM-prm / E is collected at the China Center for Type Culture Collection (CCTCC), with collection number of CCTCC V201644. A vaccine prepared by utilizing the virus can prevent the ND and the DTMUV disease and conduce to reducing virus removal after virulent NDV infection.

Description

technical field [0001] The present invention relates to the preparation and application of a live vector vaccine, in particular to the preparation and application of duck Tembusu virus prm and E protein recombinant Newcastle disease virus live vector vaccine Background technique [0002] Duck Tembusu virus disease, or duck yellow virus disease, duck hemorrhagic oophoritis, etc., is a new infectious disease that appeared in my country in 2010, and the main victims are ducks and geese. After the onset of laying ducks, the main clinical manifestations are increased body temperature, significantly decreased appetite, and a sharp drop in egg production rate or even complete laying. Symptoms at autopsy mainly manifested as follicular hemorrhage, degeneration, atrophy or dysplasia. The disease incidence rate can reach 100%, and the mortality rate is low. Meat ducks and geese can also get sick, and clinically it is mainly manifested as neurological symptoms, with a death rate of 10...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12N7/01A61K39/295A61K39/12A61K39/17A61P31/14C12R1/93
CPCA61K39/12A61K2039/552A61K2039/70C12N7/00C12N2760/18121C12N2760/18134C12N2770/24034
Inventor 孙敏华任涛李林林董嘉文张春红林秋燕
Owner INST OF ANIMAL HEALTH GUANGDONG ACADEMY OF AGRI SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com